Indication intelligence, analysis and sector perception

Lower open expected; RegMed pre-open, momentum stocks have broken down

October 13, 2015 6:53am

“Our” universe is being overwhelmed by trading as investors are relegated to the sidelines. Overnight, Asian shares slid deeper into the red in a choppy trading session on Tuesday.

Tuesday’s movers and shakers trading forecast; Subscription required: http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

DOW futures are DOWN -0.4% and NASDAQ futures are DOWN -0.5 %

U.S. stock index futures ticked lower on Tuesday, following European and Asian shares downwards, after weak trade data fueled growth concerns about China.

European stocks extended losses veering toward the lowest close in almost two weeks.

Most Asian markets fell after Chinese trade data signaled weakening global and domestic demand, the latest evidence that the world’s No. 2 economy is stalling as Chinese export data signaled a slowdown

Data docket: On Tuesday, there will also be comments from James Bullard, the president of the Federal Reserve Bank of St. Louis, who will become a voting member of the Federal Open Market Committee in January. This comes after comments from various Fed members over the past couple of days, with the centrist Dennis Lockhart reiterating the case for an interest rate lift-off this year, while Lael Brainard called for no change given downside risks.

I try to examine the conflicts in share pricing in “our” universe versus market forces. The action of volume, momentum and volatity are pitted against the who and what of the stem cell and gene therapy RegMed sector along with the consequences of alternating opening and closing actions!

Any pricing movement is now piece by piece been peeled away.

My caution remains as an old Wall Street saying is “a rising tide lifts all boats, but no matter which way the market is moving, there are stocks that will always go their own way”.

The RegMed sector closed NEGATIVE on Monday, POSITIVE on Friday, Thursday and Wednesday following a NEGATIVE close on last on Tuesday.

The RegMed sector closed MONDAY with 32 decliners, 9 advancers and 2 flats following Friday‘s POSITIVE close with 16 decliners, 25 advancers and 1 flat.

Tuesday’s trading indications:

Applied Genetic Technologies (AGTC) closed DOWN -$0.13 to $13.14, a “coiled spring” experiencing TOO much depreciation due to trading alacrity; Biogen’s BUY-IN at $20.62 is NOT even considered. The message is NOT strong enough! - Still a Strong BUY;

Capricor (CAPR) closed UP +$0.03 to $4.49 in a day’s trading range of $4.29 to $4.68. Do not be fooled by short term volume and price appreciation – it will be sold into. There are still “inside” issues in CAPR beyond filing for a $75 M mixed shelf and a pending offering - Maintaining SELL;

Cellectis ADR (CLLS) closed DOWN -$0.53 to $25.08, someone has to be “sniffing” around on the depreciation based on past interest and inference – Maintaining BUY;

Fibrocell (FCSC) closed UP +$0.35 to $4.53, overbought – SELL;

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses.

However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.